Abstract 331P
Background
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has killed over five hundred thousand people and has infected over 13 million people across the world in over 200 countries. Cancer patients fall under the high-risk category and are susceptible to the SARS-CoV-2 infection given the need for frequent hospital visits.
Methods
In this study, I analysed data from 46 cancer patients who were affected with different types of cancers (Table) and continued to receive cytotoxic treatment between January 2020 till July 2020. Table: 331P
Summary of the types of cancer and the treatment regimen of the 46 patients
Type of cancer | Number of patients | Treatment regimen |
Astrocytoma | 1 | Temodal + Bevacizumab |
Breast | 3 | EC + T |
Breast | 8 | EC + TC |
Breast | 4 | EC + THP |
Colorectal cancer | 4 | FOLFOX |
Colorectal cancer | 3 | FOLFIRI |
Colorectal cancer | 1 | FOLFOX + Bevacizumab |
Ewing sarcoma | 1 | VCD/IE |
Gastric cancer | 4 | FLOT |
Gastric cancer | 2 | XELOX |
Lung cancer | 4 | Docetaxel + Carboplatin |
Lung cancer | 1 | Topotecan |
Lung cancer | 4 | Etoposide + Carboplatin |
Lung cancer | 1 | Docetaxel + Cisplatin |
Osteosarcoma | 1 | OS99 |
Osteosarcoma | 1 | HD-MTX |
Pancreatic cancer | 2 | FOLFIRINOX |
Small bowel | 1 | FOLFOX |
Results
All the 46 patients included in the study completed their cytotoxic regimen without developing SARS-CoV-2 infection between January till July 2020.
Conclusions
The results from the study led to the hypothesis that three factors which were common among the cancer patients included in the study namely, 1) the use of granulocyte colony-stimulating factor (G-CSF), 2) the use of dexamethasone and, 3) dysbiosis of microbiome among cancer patients might be potential reasons for evading the deadly SARS-CoV-2 infection, despite their compromised immune status and a high likelihood of repeated exposure during hospital visits in comparison to the healthy general population, who are less likely to visit hospitals during the pandemic. The study aims to provide an alternate perspective and instigate discussion over the continuation of providing cancer care amidst the pandemic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session